Compare CELC & THO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | THO |
|---|---|---|
| Founded | 2011 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Homebuilding |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2017 | 1994 |
| Metric | CELC | THO |
|---|---|---|
| Price | $95.70 | $76.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $112.56 | $111.75 |
| AVG Volume (30 Days) | ★ 701.3K | 484.5K |
| Earning Date | 05-13-2026 | 06-03-2026 |
| Dividend Yield | N/A | ★ 2.67% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.59 |
| Revenue | N/A | ★ $9,579,490,000.00 |
| Revenue This Year | N/A | $1.21 |
| Revenue Next Year | $720.19 | $5.17 |
| P/E Ratio | ★ N/A | $28.89 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.42 | $69.71 |
| 52 Week High | $151.02 | $122.83 |
| Indicator | CELC | THO |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 41.93 |
| Support Level | $83.59 | $74.74 |
| Resistance Level | $95.59 | $80.73 |
| Average True Range (ATR) | 3.54 | 2.06 |
| MACD | 0.55 | -0.56 |
| Stochastic Oscillator | 74.11 | 10.21 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Based in Elkhart, Indiana, Thor Industries manufactures Class A, Class B, and Class C motor homes along with travel trailers and fifth-wheel towables across about 35 brands. Through the acquisition of Erwin Hymer in 2019, the company expanded its geographic footprint and now produces various motorized and towable recreational vehicles for Europe, including motor caravans, camper vans, urban vehicles, caravans, and other RV-related products and services. The company has also begun generating revenue through aftermarket component parts via the acquisition of Airxcel in 2021; however, this is still a nascent part of the business, as it accounted for less than 10% of fiscal 2025 total sales. In fiscal 2025, the company wholesaled 181,388 units and generated $9.6 billion in revenue.